19:45 , Mar 31, 2017 |  BC Week In Review  |  Company News

Agalimmune, BioLineRx deal

BioLineRx acquired cancer company Agalimmune for $3 million in cash and $3 million in BioLineRx shares up front, plus undisclosed milestones. Agalimmune's lead compound AGI-134 is slated to begin clinical testing to treat solid tumors...
18:44 , Nov 4, 2016 |  BioCentury  |  Emerging Company Profile

Exploiting alpha-GAL

By coating tumor cells with a synthetic carbohydrate, Agalimmune Ltd. can enlist naturally circulating polyclonal antibodies to destroy primary solid tumor cells and stimulate an adaptive immune response against metastases. The newco’s Alphaject therapies are...
07:00 , Apr 4, 2016 |  BioCentury  |  Emerging Company Profile

Sugar-coated bugs

Centauri Therapeutics Ltd .'s alphamer technology recruits a population of pre-existing, endogenous polyclonal antibodies to kill antibiotic-resistant bacteria. Centauri acquired the technology from Altermune Technologies LLC , a company founded by PCR inventor Kary Mullis....
07:00 , Sep 14, 2015 |  BioCentury  |  Politics, Policy & Law

IPR battles

A bipartisan backlash against the pricing of specialty drugs has eroded the biopharma industry's political support, leading members of Congress to question whether efforts to exempt drug patents from the inter partes review system would...
07:00 , Jun 18, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: DNA (cytosine-5-)-methyltransferase 1 (DNMT1)

Neurology INDICATION: Addiction Rat studies suggest DNMT1 inhibitors could help treat cocaine addiction. In a rat model of cocaine addiction and withdrawal, DNA methylation of multiple genes in the nucleus accumbens increased during cocaine withdrawal...
07:00 , May 28, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Galactose-α-1,3-galactosyl-β-1,4-N

Infectious disease INDICATION: Bacterial infection In vitro studies suggest bacterial-targeted conjugates of DNA aptamers and α-GAL (alphamers) could help treat bacterial infections. In co-cultures of Streptococci and human or mouse anti-α-GAL antibodies, an alphamer containing...
07:00 , May 28, 2015 |  BC Innovations  |  Product R&D

Altermune's Alphamers

Altermune Technologies LLC is taking immunotherapy back to its day job of fighting infections with a new technology that coats bacteria with a sugar, and recruits circulating antibodies against the sugar to find and destroy...
08:00 , Jan 29, 2015 |  BC Innovations  |  Product R&D

Company checkpoints

The spate of biotechs announcing new targets, combinations or milestones in the PD-1 space in the last two months suggests pharmas may not have to wait long to add second-generation therapies to their pipelines of...
08:00 , Nov 24, 2014 |  BioCentury  |  Emerging Company Profile

Breaking down ceramide

Plexcera Therapeutics LLC is developing a recombinant human acid ceramidase as a disease-modifying therapy to treat Farber disease and a subset of spinal muscular atrophy, two ultra-rare diseases for which there are no approved drugs....
07:00 , Oct 9, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) UDP-Gal:bGlcNAc b-1,4- galactosyltransferase polypeptide 6 (B4GALT6); lactosylceramide Studies in patient samples and mice suggest inhibiting B4GALT6 could help treat MS. In...